• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kodiak Sciences Inc

    3/27/25 4:33:37 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    S-8 1 kod-s8-2025_evergreen.htm S-8 S-8

     

    As filed with the U.S. Securities and Exchange Commission on March 27, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    KODIAK SCIENCES INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or other jurisdiction of incorporation or organization)

     

    27-0476525
    (I.R.S. Employer
    Identification No.)

    1250 Page Mill Road

    Palo Alto, California 94304
    (Address, including zip code, of principal executive
    offices)

     

    2018 Equity Incentive Plan
    (Full title of the plan)

     

    D. Victor Perlroth, M.D.

    Chairman and Chief Executive Officer

    1250 Page Mill Road

    Palo Alto, CA 94304

    (650) 281-0850
    (Name, address and telephone number, including
    area code, of agent for service)

     

    Copies to:

     

    David Peinsipp

    Steven M. Przesmicki

    Cooley LLP

    3 Embarcadero Center, 20th Floor

    San Francisco, California 94111

    (415) 693-2000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    

     

    Accelerated filer

    

    Non-accelerated filer

    

     

    Smaller reporting company

    

     

     

     

    Emerging growth company

    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act 

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by Kodiak Sciences Inc. (the “Registrant”) for the purpose of registering an additional 2,109,076 shares of the Registrant’s Common Stock, par value $0.0001 per share (“Common Stock”), under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”), pursuant to the provisions of the 2018 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan.

    These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the 2018 Plan are effective. The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan on Registration Statements on Form S-8 filed with the Securities and Exchange Commission on October 9, 2018 (No. 333-227755), May 15, 2019 (No. 333-231503), March 2, 2021 (No. 333-253751), May 10, 2022 (No. 333-264829), March 28, 2023 (No. 333-270907) and March 28, 2024 (No. 333-278339) (collectively, the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, the contents of such Prior Registration Statements are incorporated by reference into this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), filed with the Commission on March 27, 2025 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and

    (2) The description of the Registrant’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-38682) filed with the Commission on October 1, 2018, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.6 of the Annual Report.

     

    ITEM 8. EXHIBIT INDEX

     

     

     

     

     

     

    Incorporated by Reference

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

    4.1

     

    Amended and Restated Certificate of Incorporation of Kodiak Sciences Inc., as currently in effect.

     

    10-Q

     

    3001-38682

     

    3.1

     

    November 16, 2018

     

     

     

     

     

     

     

     

     

     

     

    4.2

     

    Amended and Restated Bylaws of Kodiak Sciences Inc., as currently in effect.

     

    10-Q

     

    001-38682

     

    3.2

     

    November 16, 2018

     

     

     

     

     

     

     

     

     

     

     

    4.3

     

    Form of Common Stock Certificate of the Company.

     

    S-1/A

     

    333-227237

     

    4.1

     

    September 24, 2018

     

     

     

     

     

     

     

     

     

     

     

    5.1*

     

    Opinion of Cooley LLP

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1*

     

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2*

     

    Consent of Cooley LLP (contained in Exhibit 5.1 hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1*

     

    Power of Attorney (contained on signature page hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.1

     

    2018 Equity Incentive Plan

     

    S-1/A

     

    333-227237

     

    10.6

     

    September 24, 2018

     

     

     

     

     

     

     

     

     

     

     

    107*

     

    Filing Fee Table

     

     

     

     

     

     

     

     

    *

    Filed herewith

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, California, on March 27, 2025.

     

    KODIAK SCIENCES INC.

     

     

     

    By:

     

    /s/ Victor Perlroth

     

     

    Victor Perlroth, M.D.

     

     

    Chairman and Chief Executive Officer

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Victor Perlroth and John Borgeson as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director or officer of Kodiak Sciences Inc.) to sign any or all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Victor Perlroth

     

    Chairman and Chief Executive Officer

     

    March 27, 2025

    Victor Perlroth, M.D.

     

    (Principal Executive Officer)

     

     

    /s/ John Borgeson

     

    Chief Financial Officer

     

    March 27, 2025

    John Borgeson

     

    (Principal Financial and Accounting Officer)

     

     

     

    /s/ Felix J. Baker

     

    Director

     

    March 27, 2025

    Felix J. Baker, Ph.D.

     

     

     

     

    /s/ Charles Bancroft

     

    Director

     

    March 27, 2025

    Charles Bancroft

     

    /s/ Bassil I. Dahiyat

     

     

     

    Director

     

     

     

    March 27, 2025

    Bassil I. Dahiyat, Ph.D.

     

     

     

     

    /s/ Richard S. Levy

     

    Director

     

    March 27, 2025

    Richard S. Levy, M.D.

     

     

     

     

    /s/ Robert A. Profusek

     

    Director

     

    March 27, 2025

    Robert A. Profusek, J.D.

     

     

     

     

     

    /s/ Taiyin Yang

     

     

    Director

     

     

    March 27, 2025

    Taiyin Yang, Ph.D.

     

     

     

     

     

     

     

     

     

     


    Get the next $KOD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    11/17/2023$7.00 → $12.00Equal Weight → Overweight
    CapitalOne
    7/27/2023$15.00 → $4.00Buy → Neutral
    UBS
    7/25/2023Buy → Neutral
    Chardan Capital Markets
    7/25/2023Neutral → Underweight
    JP Morgan
    7/24/2023Buy → Hold
    Jefferies
    More analyst ratings

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

      PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. "We are pleased to share new data from Kodiak's research and development efforts at this year's ARVO meeting. This body of work further highlights the power and versatility of Kodiak's ABC® (Antibody Biopolymer Conjugate) platform for

      5/1/25 11:43:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track." "It is remarkable that after twenty years of anti-V

      3/27/25 4:01:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

      Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significancePALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more than 250 patients into our GLOW2 Phase 3 study, exceeding our enrollment target," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak. "With its 48-week duration of treatment, all patients are expected to com

      3/10/25 4:39:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kodiak Sciences Inc

      DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:12:08 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Kodiak Sciences Inc

      DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:06:57 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Kodiak Sciences Inc

      S-8 - Kodiak Sciences Inc. (0001468748) (Filer)

      3/27/25 4:33:37 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/24 4:23:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      1/26/24 11:49:38 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/23 4:19:55 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kodiak Sciences upgraded by Jefferies with a new price target

      Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00

      12/9/24 7:57:06 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Kodiak Sciences with a new price target

      H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00

      9/5/24 7:49:18 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Kodiak Sciences with a new price target

      Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00

      12/11/23 7:49:48 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Financials

    Live finance-specific insights

    See more
    • Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

      PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

      3/26/24 6:15:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

      PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

      2/23/22 6:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    See more
    • Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

      PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

      9/17/24 4:05:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

      SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

      12/3/20 11:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Borgeson John A.

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:52:43 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chairman and CEO Perlroth Victor

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:48:10 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      7/2/24 4:49:54 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care